CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Somatotropindrug
Likely dose
Somatotropin 0.012 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00591760
NCT00591760Phase 2Completed
CompareCT.gov

Correction of Growth Hormone Deficiency in Patients With Chronic Heart Failure: a Randomized, Controlled, Single-blind Study

Federico II University·interventional·Posted Jan 11, 2008·Updated Nov 19, 2012

In Brief

A Phase 2 clinical trial evaluating Somatotropin for Heart Failure and 2 related conditions. Completed, enrolled 56 participants.

Detailed Summary

The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Growth Hormone Deficiency, Ischemic Heart Disease
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2008
Enrollment StartDec 1, 2004
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.5 years ago

Interventions

Somatotropindrug

Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months